drugset / Trial / NCT01597349

Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

NCT01597349

Phase 2 Completed 208 enrolled Avalo Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this research study is to learn how effective and safe FP01 lozenges are when given to subjects with a cough due to an upper respiratory tract infection. The study will include subjects who have an upper respiratory tract infection, with a cough of less than six weeks duration.

Timeline

Start
2012-05
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown

Indications

No indication recorded.